DrugInformer Search

Kawasaki's Disease : Human Immunoglobulin G Vs. Aspirin

Definition

Kawasaki disease (KD), also known as Kawasaki syndrome, lymph node syndrome and Mucocutaneous lymph node syndrome, is an autoimmune disease that manifests as a systemic necrotizing medium-sized vessel vasculitis and is largely seen in children under 5 years of age. It affects many organ systems, mainly those including the blood vessels, skin, mucous membranes and lymph nodes; however, its most serious effect is on the heart where it can cause severe coronary artery aneurysms in untreated children. Without treatment, mortality may approach 1%, usually within 6 weeks of onset. With treatment, the mortality rate is less than 0.01% in the U.S. There is often a pre-existing viral infection that may play a role in its pathogenesis. The conjunctival and oral mucosa, along with the epidermis (skin), become erythematous (red and inflamed). Edema is often seen in the hands and feet and the cervical lymph nodes are often enlarged. Also, a remittant fever, often 40℃ (104°F) or higher, is characteristic of the acute phase of the disease. In untreated children, the febrile period lasts on average approximately ten days, but may range from 5 to 25 days. The disorder was first described in 1967 by Dr. Tomisaku Kawasaki in Japan.

Read more on Wikipedia

Compare Drugs

Please add a drug to the list to compare them side by side.
Add a new Drug

* Warning: The facts and figures contained in these reports are accurate to the best of our capability; however, our metrics are only meant to augment your medical knowledge, and should never be used as the sole basis for selecting a new medication. As with any medical decision, be sure to work with your doctor to ensure the best choices are made for your condition.

* About FAERS: The FDA Adverse Event Reporting System (FAERS) is used by FDA for activities such as looking for new safety concerns that might be related to a marketed product, evaluating a manufacturer's compliance to reporting regulations and responding to outside requests for information. Reporting of adverse events is a voluntary process, and not every report is sent to FDA and entered into FAERS. The FAERS database may contain duplicate reports, the report quality is variable, and many factors may influence reporting (e.g., media attention, length of time a drug is marketed, market share). For these reasons, FAERS case reports cannot be used to calculate incidence or estimates of risk for a particular product or compare risks between products.